Read This First
This page is not built on clinical evidence. It is built on the regulatory record, the statements of the company that developed the compound, and the analytical chemistry literature. None of it tests whether AOD-9604 works; the trials that did are covered on the library entry, and they were negative.
AOD-9604 is an orphaned compound. The company that designed it, tested it in 925 people and owned the patents does not manufacture, distribute or sell it, and said so in writing in 2013.1 Every vial on the market therefore comes from somewhere with no connection to the material that was ever characterised, and that is the fact the rest of this page follows from.
Legal Status
Where Does AOD-9604 Stand?
Approved nowhere, for anything. The developer's own statement: it "has not been granted approval by Australia's Therapeutic Goods Administration or any other government health authority in the world to be marketed as a pharmaceutical product."1
In the United States it sits in a specific regulatory position. In September 2023 the FDA placed it in Category 2 of its interim policy on substances nominated for compounding, the category for substances that may present significant safety risks. As of April 2026 it appears under "bulk drug substances nominated but withdrawn", with the agency's safety text unchanged.2
What Does the FDA Say About It?
The agency's entry reads, in full: compounded drugs containing AOD-9604 "may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has identified no, or only limited, safety-related information. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans. FDA has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear."2
Two phrases in that paragraph do most of the work. "Certain routes of administration" means injection, which is how the gray market sells it and how the human trials did not test it. And "serious adverse events that may be associated" is the FDA saying it has reports it cannot attribute, which is more than it says for most peptides on the same list. Read it alongside the agency's fuller 2024 review, which searched its adverse event reporting system and the literature through January 2024 and found no reports for AOD-9604 by any route, while cautioning that absence of reports for a compounded product does not imply safety.11 The five cancers recorded among trial participants, all judged unrelated by the sponsor, are the most likely referent of the earlier sentence; the FDA does not say.9
Can It Be Compounded?
Not lawfully in the United States. AOD-9604 is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list.
It has, however, been formally considered for that list and rejected. On 4 December 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed AOD-9604 free base and acetate for obesity. The FDA's review found a lack of evidence of effectiveness by any route, no human exposure data for subcutaneous injection, and genotoxicity signals it declined to dismiss; it proposed against inclusion, and the committee voted 0 to 12 against.1112 It was not among the seven peptides the same committee considered in July 2026, so the advisory votes that generated headlines that month have no bearing on it.3
The company's 2013 statement said Australian doctors could prescribe it through compounding pharmacies.1 That was a claim about Australian compounding practice thirteen years ago; ONPEPS has not verified its current standing, and it says nothing about any other jurisdiction.
What About "GRAS"?
The status is routinely presented as an FDA safety endorsement. It is not one.
In June 2012 a panel of experts convened for the company concluded AOD-9604 was Generally Recognised As Safe for its intended use in foods, drinks and dietary supplements, at up to 1 mg a day by mouth, conditional on publication of the existing safety data.1 A search of the FDA's GRAS Notice Inventory for AOD9604 returns no records, meaning no notice was filed and the FDA has expressed no view.4
A self-affirmed food-use opinion for oral intake at 1 mg a day is not evidence about a vial of powder intended for injection. A seller quoting the GRAS status on an injectable product page is describing a different product, a different route and a different regulator.
Product Identity
What Is Being Sold Under This Name?
Unknown in any individual case, and here the point is sharper than usual.
AOD-9604 is a 16-residue peptide with a disulfide bridge between two cysteines.5 Getting the sequence right is the easy part of synthesis. Getting the bridge to form correctly, without the linear or mis-paired forms that also have the same mass, is harder, and it is the kind of detail that separates a characterised active ingredient from a powder with the right name. The FDA's phrase for this is "complexities with regard to peptide-related impurities and API characterization."2
The developer told the Australian Securities Exchange in 2010 that the compound was being manufactured in China and elsewhere and sold in breach of its patents to distributors, gyms, weight-control centres, clinics and individuals.1 That is the supply chain, described by the patent holder.
What Has Been Found in Seized Product?
Belgian authorities seized unknown pharmaceutical preparations that turned out to contain AOD-9604, and the national laboratory published a case report on identifying and characterising them by mass spectrometry.6 A United States anti-doping laboratory noted in 2015 that the peptide was available on several websites and had recently been identified in confiscated vials.5
Those are the documented sightings. What neither paper provides, and what ONPEPS could not find anywhere, is a systematic survey of gray-market AOD-9604 with a stated sample count, a purity distribution and a mislabelling rate. Figures of that kind circulate for this class of product; where they are quoted without a laboratory, a method and a denominator, they are not measurements.
Purity Testing Versus Identity Testing
| Test | Question it answers | Question it cannot answer |
|---|---|---|
| HPLC purity | What proportion of the sample is a single main peak | Which molecule that peak is, or whether the disulfide is correctly formed |
| Mass spectrometry identity | Whether the molecular mass matches AOD-9604 | How much of the sample it represents; a mis-paired isomer has the same mass |
| Endotoxin assay | Whether bacterial cell-wall fragments are present | Identity or content |
| Sterility | Whether viable organisms are present | Anything about the peptide |
A certificate reporting a purity percentage and nothing else has answered one of four questions. For a cyclic peptide, even a mass match is not proof of the correct structure.
Certificates of Analysis
What a Certificate Is
A laboratory report on one batch. Read it for the laboratory's name and whether it is independent of the seller, the lot number and whether it matches the vial, the date, and which tests were actually run as opposed to which the product page mentions.
What It Cannot Establish
That the vial in hand came from the batch described. The value of the document rests on a chain of custody between laboratory, seller and buyer that the buyer cannot inspect. A certificate is a PDF, and nothing about the format prevents reuse or fabrication. The FDA has documented fabricated labels and fictitious pharmacy names on gray-market peptide products in the GLP-1 market; there is no reason to think the AOD-9604 market, which is smaller and less scrutinised, is cleaner.7
"Research Use Only"
Does the Label Change Anything?
No. The label is a liability position adopted by the seller, not a regulatory category. The FDA has held, in warning letters to peptide sellers, that a research-use disclaimer does not survive product copy that establishes the product is intended for human use; the totality of the page determines intended use, not the sentence that contradicts the rest of it.8
A product page that describes fat loss, "clinically proven" safety and a dosing schedule, and then says the vial is not for human consumption, has made the agency's argument for it.
The Route Problem
Why Does It Matter That the Trials Were Oral?
Because the one thing AOD-9604 genuinely has, a human safety record, was generated by a route nobody on the gray market uses.
The six company trials dosed the compound intravenously in the early studies and by mouth in the later ones.9 Retail product is lyophilised powder sold for subcutaneous injection. Subcutaneous administration of a peptide is exactly the setting in which aggregation and impurities become immunogenicity questions, and it is the route the FDA says it has no safety information for.2
The safety record is real. It just belongs to a different product.
Storage and Handling
What Is Known
No manufacturer-validated storage specification exists for any product a consumer can buy, because no approved product exists. The company's pharmacokinetic work reported an intravenous half-life of about three minutes in pigs, which describes clearance in the body rather than shelf stability, but does indicate a molecule that is not built to persist.10
What can be stated is general peptide chemistry. Lyophilised powder is more stable than solution. Cysteine-containing peptides are vulnerable to oxidation, which can scramble or break the disulfide bridge without any visible change. Heat and repeated freeze-thaw cycles degrade peptides in solution. Every specific duration quoted online for reconstituted AOD-9604 is extrapolated from other molecules.
Multi-Dose Vials
Gray-market product is supplied as a multi-dose vial to be reconstituted with bacteriostatic water. The FDA's guidance for compounded injectables is to discard a multi-dose vial within 28 days of first use regardless of what remains or what the supplier says, and to use a new sterile needle and syringe for every dose.7
Signs to Stop Rather Than Proceed
Powder that does not dissolve cleanly, or a solution that stays cloudy or shows particulate after gentle mixing
Any discoloration of powder or solution
A wet or collapsed cake where a dry one is expected
A lot number, label or certificate that does not match the order
Redness, swelling or induration at injection sites that grows with successive doses, which is the pattern an immune response takes
None of these distinguishes between a wrong molecule, a degraded one and a contaminated one. Appearance rules out some problems and confirms nothing.
Community Language
AOD-9604, hGH Frag 176-191, "Frag"
The same compound. The residue numbers describe the region of growth hormone the peptide copies; the product itself is a 16-residue synthetic with an added tyrosine.5
Lipolytic fragment
The mechanistic label from the animal work. It describes what the peptide did in obese rodents, not what the human trials found.
GRAS
A self-determined food-safety status for oral use at 1 mg a day, made by a company-convened panel with no FDA notice on file.4
Category 2
The FDA's interim classification for nominated compounding substances that may present significant safety risks. AOD-9604 was placed there in 2023 and is now listed as nominated but withdrawn.2
Research use only
A seller's disclaimer. Not a regulatory category, and not a defence the FDA has accepted where the marketing says otherwise.8
Certificate of analysis
A laboratory report on one batch. It describes the batch tested, not necessarily the vial received.
Related ONPEPS Coverage
AOD-9604 library entry: the trials, the result and the regulatory position
Compounded, gray market and counterfeit semaglutide: what the regulators have documented
FDA peptide news July 2026: the compounding vote and what it did not cover
Sources
Calzada Ltd / Metabolic Pharmaceuticals Pty Ltd. AOD9604 – Important Clarifications. Company statement, 26 April 2013. lateral-pharma.com
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for AOD-9604. Content current as of 22 April 2026. fda.gov
US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. fda.gov
US Food and Drug Administration. GRAS Notice Inventory, search for "AOD9604". Returns no records. Searched 16 September 2026. hfpappexternal.fda.gov
Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-38. Paywalled. pubmed.ncbi.nlm.nih.gov/25208511
Vanhee C, Moens G, Deconinck E, De Beer JO. Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. Drug Test Anal. 2014;6(9):964-968. Paywalled. pubmed.ncbi.nlm.nih.gov/24976118
US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug Alerts and Statements. Cited for the agency's general guidance on multi-dose vials and fabricated labels. fda.gov
US Food and Drug Administration. Warning Letter: Gram Peptides. MARCS-CMS 721806, 31 March 2026. fda.gov
Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. Open access; not indexed in PubMed; co-authored by the sponsor's chief executive. doi.org/10.4021/jem157w
Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77. Open access; not indexed in PubMed; co-authored by the sponsor's chief executive. doi.org/10.14740/jem213w
US Food and Drug Administration. AOD-9604-related bulk drug substances: FDA review for the December 4, 2024 meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2024-N-4777. fda.gov
US Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. Approved 21 February 2025. fda.gov
Not Medical Advice
AOD-9604 holds no marketing authorisation for human use in any jurisdiction. If you are already using a product obtained outside a pharmacy, the route back to oversight is a clinician who knows what you have taken.
Regulatory sources verified 16 September 2026. The FDA's compounding categories are under active revision and the record changes frequently. Re-verify before relying on any statement here.